Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine

29

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate Vaxart’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Under the agreement Vaxart will produce an oral vaccine…

 

 

 

http://www.businesswire.com/news/home/20190709005100/en/Vaxart-Enters-Research-Collaboration-Janssen-Evaluate-Oral